<DOC>
	<DOC>NCT01219855</DOC>
	<brief_summary>This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT).</brief_summary>
	<brief_title>Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>1. Urinary albumin excretion of ≤3000 μg of creatinine 2. Stage 3 CKD 3. Plasma iPTH: &gt; 70 pg/mL and &lt; 500 pg/mL 4. Serum Ca: ≥ 8.4 mg/dL and &lt; 10.0 mg/dL 5. Serum P: ≥ 2.0 mg/dL and &lt; 5.0 mg/dL 6. Serum 25hydroxyvitamin D: &gt; 10 ng/mL and &lt; 29 ng/mL. 7. Discontinue vitamin D use for duration of study 1. History of kidney transplant or parathyroidectomy 2. Spot urine calcium:creatinine ratio &gt; 0.2 3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis 4. Currently on dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Parathyroid Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Kidney Failure, Chronic</keyword>
	<keyword>Hyperparathyroidism, Secondary</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>Renal Insufficiency, Chronic</keyword>
</DOC>